{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:10:05Z","timestamp":1791051005382,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T00:00:00Z","timestamp":1274745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00228-010-0835-0","type":"journal-article","created":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T09:39:39Z","timestamp":1274693979000},"page":"871-877","source":"Crossref","is-referenced-by-count":53,"title":["CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking"],"prefix":"10.1007","volume":"66","author":[{"given":"Margareta","family":"Ramsj\u00f6","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilleba","family":"Bohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ingelman-Sundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Keun","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,25]]},"reference":[{"issue":"1","key":"835_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2515\/therapie:2004003","volume":"59","author":"K Brosen","year":"2004","unstructured":"Brosen K (2004) Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 59(1):5\u201312","journal-title":"Therapie"},{"issue":"4","key":"835_CR2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/clpt.1989.40","volume":"45","author":"L Bertilsson","year":"1989","unstructured":"Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45(4):348\u2013355","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"835_CR3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.1991.tb05594.x","volume":"31","author":"SA Ward","year":"1991","unstructured":"Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism\u2014a panel study. Br J Clin Pharmacol 31(6):689\u2013692","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"835_CR4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","volume":"32","author":"XQ Li","year":"2004","unstructured":"Li XQ, Andersson TB, Ahlstrom M, Weidolf L (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32(8):821\u2013827","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"835_CR5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2125.1993.tb00410.x","volume":"36","author":"T Andersson","year":"1993","unstructured":"Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36(6):521\u2013530","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"835_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1067\/mcp.2000.108949","volume":"68","author":"K Laine","year":"2000","unstructured":"Laine K, Tybring G, Bertilsson L (2000) No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 68(2):151\u2013159","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"835_CR7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00008571-199512000-00004","volume":"5","author":"M Chang","year":"1995","unstructured":"Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5(6):358\u2013363","journal-title":"Pharmacogenetics"},{"issue":"6","key":"835_CR8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/BF00316090","volume":"39","author":"G Alvan","year":"1990","unstructured":"Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39(6):533\u2013537","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"835_CR9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2125.1985.tb02673.x","volume":"19","author":"M Jurima","year":"1985","unstructured":"Jurima M, Inaba T, Kadar D, Kalow W (1985) Genetic polymorphism of mephenytoin p(4\u2032)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 19(4):483\u2013487","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"835_CR10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.1985.194","volume":"38","author":"K Nakamura","year":"1985","unstructured":"Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38(4):402\u2013408","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"835_CR11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/clpt.1989.126","volume":"46","author":"Y Horai","year":"1989","unstructured":"Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, Liao CL, Zhang LM (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46(2):198\u2013207","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"835_CR12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/clpt.1992.38","volume":"51","author":"L Bertilsson","year":"1992","unstructured":"Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51(4):388\u2013397","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"835_CR13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00007691-199404000-00018","volume":"16","author":"T Ishizaki","year":"1994","unstructured":"Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Andersson T, Regardh CG, Lou YC, Zhang Y et al (1994) Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 16(2):214\u2013215","journal-title":"Ther Drug Monit"},{"issue":"6","key":"835_CR14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00008571-199612000-00008","volume":"6","author":"HK Roh","year":"1996","unstructured":"Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L (1996) CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6(6):547\u2013551","journal-title":"Pharmacogenetics"},{"issue":"22","key":"835_CR15","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SM Morais de","year":"1994","unstructured":"De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269(22):15419\u201315422","journal-title":"J Biol Chem"},{"issue":"4","key":"835_CR16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","volume":"46","author":"SM Morais De","year":"1994","unstructured":"De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46(4):594\u2013598","journal-title":"Mol Pharmacol"},{"issue":"1","key":"835_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103\u2013113","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"835_CR18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/dmd.32.5.484","volume":"32","author":"M Sandberg","year":"2004","unstructured":"Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E (2004) The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 32(5):484\u2013489","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"835_CR19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00228-007-0438-6","volume":"64","author":"N Djordjevic","year":"2008","unstructured":"Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 64(4):381\u2013385","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"835_CR20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","volume":"63","author":"R Ghotbi","year":"2007","unstructured":"Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L (2007) Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63(6):537\u2013546","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"835_CR21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9236(03)00050-X","volume":"73","author":"M Christensen","year":"2003","unstructured":"Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73(6):517\u2013528","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"835_CR22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0009-9236(97)90060-6","volume":"62","author":"G Tybring","year":"1997","unstructured":"Tybring G, Bottiger Y, Widen J, Bertilsson L (1997) Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 62(2):129\u2013137","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"835_CR23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00008571-199704000-00004","volume":"7","author":"HG Xie","year":"1997","unstructured":"Xie HG, Huang SL, Xu ZH, Xiao ZS, He N, Zhou HH (1997) Evidence for the effect of gender on activity of (S)-mephenytoin 4\u2032-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 7(2):115\u2013119","journal-title":"Pharmacogenetics"},{"issue":"4","key":"835_CR24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/clpt.2009.2","volume":"85","author":"A Gomez","year":"2009","unstructured":"Gomez A, Ingelman-Sundberg M (2009) Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 85(4):426\u2013430","journal-title":"Clin Pharmacol Ther"},{"issue":"7258","key":"835_CR25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/nature08211","volume":"460","author":"JI Kim","year":"2009","unstructured":"Kim JI, Ju YS, Park H, Kim S, Lee S, Yi JH, Mudge J, Miller NA, Hong D, Bell CJ, Kim HS, Chung IS, Lee WC, Lee JS, Seo SH, Yun JY, Woo HN, Lee H, Suh D, Kim HJ, Yavartanoo M, Kwak M, Zheng Y, Lee MK, Kim JY, Gokcumen O, Mills RE, Zaranek AW, Thakuria J, Wu X, Kim RW, Huntley JJ, Luo S, Schroth GP, Wu TD, Kim H, Yang KS, Park WY, Church GM, Lee C, Kingsmore SF, Seo JS (2009) A highly annotated whole-genome sequence of a Korean individual. Nature 460(7258):1011\u20131015","journal-title":"Nature"},{"issue":"3","key":"835_CR26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002280050615","volume":"55","author":"WJ Tamminga","year":"1999","unstructured":"Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, de Zeeuw RA, Jonkman JH (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55(3):177\u2013184","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"835_CR27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.2001.01328.x","volume":"51","author":"S Hagg","year":"2001","unstructured":"Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51(2):169\u2013173","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"835_CR28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1046\/j.1365-2125.2003.01868.x","volume":"56","author":"S Palovaara","year":"2003","unstructured":"Palovaara S, Tybring G, Laine K (2003) The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol 56(2):232\u2013237","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"835_CR29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S0950268806006613","volume":"135","author":"T Suzuki","year":"2007","unstructured":"Suzuki T, Matsuo K, Sawaki A, Wakai K, Hirose K, Ito H, Saito T, Nakamura T, Yamao K, Hamajima N, Tajima K (2007) Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol Infect 135(1):171\u2013176","journal-title":"Epidemiol Infect"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0835-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-010-0835-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0835-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:36:16Z","timestamp":1740105376000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0835-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,25]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0835-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,25]]}}}